Spirometer Market Outlook: Respiratory Care Demand and Growth Opportunities

Rising prevalence of respiratory diseases such as asthma and COPD, increasing air pollution, and growing awareness of lung health are driving growth in the spirometer market. Expansion of pulmonary function testing in hospitals and clinics supports demand. According to IMARC Group's latest research publication, The global spirometer market size reached USD 1,227.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,468.2 Million by 2033, exhibiting a growth rate (CAGR) of 7.67% during 2025-2033.

How AI is Reshaping the Future of Spirometer Market

• Automated Diagnostic Accuracy and Pattern Recognition: AI technology can automatically analyze spirometry data to detect chronic obstructive pulmonary disease (COPD) and asthma with accuracy above 95%, compared to conventional methods. In clinical use, the accuracy of diagnosis has improved from 38% to 68%.
• Real-Time Quality Control and Test Validation: Machine learning algorithms can quickly assess the quality of a spirometry maneuver during the measurement and inform the patient on-the-spot if it is adequate and whether it meets clinical validation criteria, considerably reducing the number of poor-quality spirometries and enabling home monitoring.
• Predictive Health Analytics for Disease Progression: Advanced algorithms from artificial intelligence using home spirometry data can predict lung function decline and respiratory exacerbations days ahead of noticeable symptoms. This enables early intervention and avoiding hospital admissions by continuously monitoring patient status and sending clever alerts to high-risk patients at home.

Explore Updated 2026 Market Trends & Analysis

Spirometer Industry Overview:

Government health surveillance activities continue to improve respiratory testing with increased screening and mandatory testing. The NIOSH Coal Workers' Health Surveillance Program (CWHSP) completed 1,934 spirometry tests at its 50 certified clinics, the highest number since 2020, and through the agency's mobile examination unit program in underrepresented areas of the coal mining regions of Pennsylvania, Ohio, Maryland and West Virginia. Home use spirometers are now FDA-approved, including the NuvoAir Air Next device for regular at home pulmonary function testing among patients with chronic obstructive pulmonary disease (COPD), asthma, and amyotrophic lateral sclerosis (ALS).

Spirometer Market Trends & Drivers

The burden of chronic respiratory disease worldwide is the main factor driving the global uptake of spirometers. The World Health Organization estimates that about 390 million people are affected by COPD worldwide, with over 262 million affected by asthma. Asthma affects 14% of children worldwide (334 million people), with numbers projected to increase by 100 million by 2025 due to urbanization and pollution (Global Asthma Report). COPD is the third leading cause of death worldwide, killing more than 3 million people every year. Direct healthcare costs for COPD are over USD 40 billion per year in Europe alone, and unprecedented investment in early detection has occurred.

The increase in home health care and portable medical devices has enabled respiratory monitoring outside of the customary medical environment. The FDA has approved some spirometers for home use, making it possible for patients to take lung tests at home. Globally, more than 2.5 million home spirometers have been used. Portable wireless spirometers, smart-phone based data platforms, and cloud-based remote monitoring systems are increasing the ability of providers to monitor the progress, performance and patient outcomes. An example is AioCare by Vyaire Medical, a mobile spirometry system that was launched in 15 countries. ArtiQ has worked with AstraZeneca to allow simple tests of lung capacity for participants in clinical trials from the comfort of their home.

Innovations in technology and collaborative approaches have yielded new opportunities for growth through device and market development, such as digital spirometers with artificial intelligence, automated calibration, and EHR integration to improve diagnostic accuracy and workflow efficiency. Major acquisitions for pulmonary function testing (PFT) include CAIRE Inc. acquiring PFT subsidiary MGC Diagnostics, as well as calculated partnerships between pharmaceutical and medical device companies like AstraZeneca India and Alveofit to create IoT-enabled handheld spirometers. AI-assisted platforms Clario and ArtiQ have merged to improve data collected in clinical trials. Regulatory efforts like NIOSH-approved spirometry training programs for portable and laboratory spirometry improve the skills of professionals who operate systems in a variety of healthcare settings.

Leading Companies Operating in the Global Spirometer Industry:

• Benson Medical Instruments
• Chest M.I.
• Fukuda Sangyo
• Hill-Rom Inc.
• Jones Medical Instrument Company
• Medical International Research
• Midmark Corporation
• NDD Medizintechnik AG
• Schiller AG
• Vitalograph
• Vyaire Medical
• Welch Allyn Inc.

Spirometer Market Report Segmentation:

By Product:

• Consumables & Accessories
• Devices
• Software

By Mechanism:

• Flow-Sensing Spirometers
• Peak Flow Meters
• Others

By Application:

• COPD
• Asthma
• Others

By Disposable Components:

• Filters
• Tubes
• Sensors

By End-User:

• Hospitals
• Clinical Laboratories
• Home Care Settings
• Others

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Recent News and Developments in Spirometer Market

• January 2024: NuvoAir Medical was granted 510(k) clearance from the FDA for the Air Next Spirometer, the first spirometer to be approved for a full lung function test from the home, giving patients with COPD, asthma, and ALS a way to remotely and continuously monitor lung function. It also expanded clinical options for heart and lung diseases.
• In March 2023, Clario and ArtiQ announced an agreement to deliver the AI-assisted collection of spirometry data into clinical trials, providing AI over-reading at scale, accurate data collection, and improved patient benefit in respiratory clinical research, showing the pharmaceutical industry's commitment to advanced diagnostic technology.
• In November 2022, CAIRE Inc. announced the acquisition of MGC Diagnostics Holdings Inc., expanding the CAIRE Inc. product line available in the cardiorespiratory diagnostics marketplace, to include cardiopulmonary exercise systems, spirometers, flow sensors, gas analyzers and consumables, in addition to pulmonary function testing systems.
• August 2022: AstraZeneca India and Alveofit provided IoT handheld spirometers to primary care clinics and last-mile hospitals across India to help ease access to advanced respiratory diagnostics capabilities in under-served healthcare facilities, showing the role of the pharmaceutical industry in expanding diagnostic infrastructure.
• March 2021: Vyaire Medical launched the AioCare mobile respiratory spirometry system, expanding the adoption of portable spirometry with mobile connectivity and real-time data analysis in over 15 countries worldwide, including Australia, where the technology will help improve respiratory care for patients and healthcare professionals alike.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.